Inside Kennedy's Vaccine Playbook: What a Leaked HHS Document Tells Us
A new HHS document reveals fresh details about RFK Jr.'s plans to overhaul federal vaccine policy, from splitting up the MMR shot to creating entirely new recommendation categories. For vaccine makers already reeling from 18 months of policy shifts, the 30-day comment period feels less like a question and more like a foregone conclusion.
The Quiet Document That Has Vaccine Makers Sweating
Somewhere inside HHS, someone hit "publish" on a request for information. It's not a new law. It's not a regulation. It's basically a government Google Form asking for public feedback on vaccine policy. And yet, it might be the most important signal for the vaccine industry all year.
STAT News reported on the document this week, and it reveals new details about how Robert F. Kennedy Jr. plans to reshape how the federal government thinks about vaccines. The request asks whether HHS should create entirely new categories for vaccine recommendations, moving beyond the current system of universal recommendations, risk-based recommendations, and shared clinical decision-making (where parents and doctors decide together).
Think of it like this: the current vaccine framework is a menu with three items. Kennedy wants to know if it should have five. Or seven. Or maybe a completely different restaurant.
What the Document Actually Says
The HHS request for information gives the public 30 days to weigh in. On its own, it changes nothing. But paired with an August 10 executive order that preceded it, the picture becomes much clearer.
That executive order tells HHS to do three specific things within 90 days:
Develop plans to offer single-vaccine alternatives, starting with MMR (measles, mumps, rubella). Right now, those three shots come bundled together like a cable package. Kennedy wants an à la carte option, while still keeping the combo available.
Reassess the timing and sequencing of childhood vaccines. When kids get which shots, and in what order, could change based on what the administration calls "gold-standard science."
Adjust the federal childhood vaccine schedule as appropriate. That's broad language, and it's meant to be.
The order also pushes for stronger religious and medical exemptions from school vaccination requirements. It even directs the Justice Department to challenge state laws that the administration sees as conflicting with parental authority on vaccines.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This isn't a theoretical exercise. It's a policy roadmap.
18 Months of Dominoes
To understand why this document matters, you need to see the pattern. Kennedy hasn't been sitting idle since taking office. He's been systematically reshaping vaccine policy, one move at a time, like someone rearranging every piece of furniture in a house while the family is still living in it.
In February 2025, he canceled the CDC's flu vaccination campaign. A month later, he forced out Peter Marks, the FDA's top vaccine regulator. By May, HHS had removed COVID-19 vaccine recommendations for healthy children and pregnant women, without the traditional advisory committee vote.
Then came June 2025: Kennedy fired all 17 members of ACIP, the CDC's vaccine advisory committee. The reconstituted panel reaffirmed routine annual influenza vaccination for all persons aged 6 months and older, though it added a requirement for thimerosal-free, single-dose formulations for certain groups. In August 2025, HHS canceled roughly $500 million in mRNA vaccine development funding.
By January 2026, the U.S. had ended universal childhood vaccine recommendations for flu, rotavirus, meningococcal disease, and hepatitis A. Those shifted to "shared clinical decision-making," putting more weight on individual parent-doctor conversations rather than blanket guidance.
Each step seemed incremental. Together, they represent the most dramatic overhaul of U.S. vaccine policy in modern history.
Wall Street's Vaccine Hangover
Investors saw this coming, and they've been selling accordingly. BioNTech, Novavax, and Vaxcyte all sold off too. Even the broad biotech ETFs (XBI and IBB) took hits.
The calculus is straightforward: fewer recommendations mean fewer shots, which means less revenue. And the companies most exposed are the ones most dependent on vaccines for their business.
Moderna sits at the top of the risk list. Its entire business model revolves around mRNA vaccines. When the government narrows who should get those shots, Moderna's addressable market shrinks. Analysts describe the policy shift as a multi-year drag on demand, not a one-quarter blip.
Merck is also heavily exposed, thanks to Gardasil (HPV vaccine) and its MMR franchise. Both depend on school-age vaccination schedules; if those schedules loosen, Merck feels it directly. Pfizer has more cushion because its revenue base is broader, but Prevnar 20 and its COVID vaccine still tie it to CDC-endorsed recommendations.
Sanofi, with its flu and pediatric vaccine portfolio, faces moderate risk. Large and diversified enough to absorb some damage, but not immune to declining U.S. vaccination rates that are already showing up in earnings.
The "It's Just a Comment Period" Defense
HHS would tell you this is routine governance: asking the public for input before making decisions. That framing isn't wrong, exactly. Federal agencies do this all the time.
But context matters. When a request for information comes after 18 months of fired advisors, canceled funding, narrowed recommendations, and an executive order with a 90-day deadline, "just asking questions" starts to look a lot like "previewing the answer."
Public health experts have been sounding alarms throughout this process. Critics argue that Kennedy's approach risks confusing families, weakening evidence-based policy, and creating space for vaccine misinformation to fill the gaps left by withdrawn federal guidance. Some courts and parts of the federal bureaucracy have pushed back, but the overall trajectory has been clear.
What Happens Next
The 30-day comment period will close in late September 2026. After that, HHS can use the responses to justify whatever framework changes it was already considering. The 90-day clock on the executive order's directives ticks into November, which means we could see concrete proposals for single-dose MMR alternatives and schedule changes before year's end.
For vaccine makers, the investment thesis has fundamentally shifted. This isn't about one bad quarter or a single policy tweak. It's about whether the U.S. government will continue to be the world's most reliable engine of vaccine demand, or whether that engine is being deliberately downgraded.
The document is technically a question. But everyone in biotech already knows which direction the answer is heading.
Clinical & Regulatory5 min read
Capricor's Duchenne Drug Just Hit a Wall. Then the Activist Investors Showed Up.
Capricor's cell therapy for Duchenne muscular dystrophy faces a likely FDA rejection after advisors voted 9-to-3 against it, and activist investor Kaos Capital is simultaneously demanding a full boardroom overhaul. It's a two-front war that could determine the company's survival.
